Ignite Creation Date:
2024-05-06 @ 7:16 AM
Last Modification Date:
2024-10-26 @ 11:47 AM
Study NCT ID:
NCT02507492
Status:
UNKNOWN
Last Update Posted:
2016-02-22
First Post:
2015-05-29
Brief Title:
RM-493 Treatment Trial in Proopiomelanocortin POMC Deficient Patients
Sponsor:
Charite University Berlin Germany
Organization:
Charite University Berlin Germany
Study Overview
Official Title:
RM-493 Treatment Trial in Proopiomelanocortin POMC Deficient Patients
Status:
UNKNOWN
Status Verified Date:
2016-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the effects of a once daily subcutaneous SC injection of RM-493 in subjects with POMC propiomelanocortin or other related rare genetic mutations on body weight metabolic function and blood pressure Patients who respond during the initial 84 days of treatment can enter into long-term 2-year extensions The study drug RM-493 will be administered in an unblinded fashion
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2014-002392-28 | EUDRACT_NUMBER | None | None |